Drawing for XYZAGEN

USPTO serial 99230506

XYZAGEN

Reviewed by CopyMark Law Group

Reg. 8554022Status 700Registered
Filing date
Status date
Registration date
Nov 17, 2026
Examiner
DANG, PETER T
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with XYZAGEN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Melissa A. Vallone

Melissa A. Vallone Barnes & Thornburg LLPOne North Wacker Drive, Suite 4400Chicago, IL 60606United States

Goods and services

ClassDescriptionStatusFirst use
035Business management services for nonclinical and clinical pharmacology pharmaceutical drug development programsACTIVEMar 26, 2025
042Pharmaceutical drug development consulting services, pharmacology and pharmacokinetics advisory services in the nature of consultancy services, and scientific research services in the nature of bioanalysis and pharmacokinetic modeling and simulation; Providing scientific information in the fields of pharmacokinetics, clinical research study design, behavioral pharmacology, neurology, ophthalmology, anti-infective and respiratory pharmacology drug development within pharmacokinetics, clinical pharmacokinetics, and pharmacokinetics modeling and simulationACTIVEMar 26, 2025
044Providing health information in the fields of pharmacokinetics, behavioral pharmacology, neurology, ophthalmology, clinical pharmacokinetics, and pharmacokinetics modeling and simulationACTIVEMar 26, 2025

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 17, 2026NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Nov 17, 2026R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Oct 28, 2026SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Oct 28, 2026CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Oct 20, 2026SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Oct 15, 2026IUAFUSE AMENDMENT FILED—
Oct 15, 2026EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Apr 21, 2026NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 24, 2026NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 24, 2026PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 18, 2026NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 27, 2026CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 27, 2026XAECEXAMINER'S AMENDMENT ENTERED—
Jan 27, 2026GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jan 27, 2026GNEAEXAMINERS AMENDMENT E-MAILED—
Jan 27, 2026CNEAEXAMINERS AMENDMENT -WRITTEN—
Jan 21, 2026TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 21, 2026CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 21, 2026TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 3, 2025GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 3, 2025GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 3, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 31, 2025DOCKASSIGNED TO EXAMINER—
Oct 27, 2025MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Oct 27, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 12, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Jun 12, 2025NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance